Oct 2, 2020
Learn about the discovery of immunodeficiencies leading to the use of pooled immunoglobulin as therapy, the struggle to use it intravenously and the eventual use in autoimmune disease.
Disclosure: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Barandun S, et al. Vox Sang. 1962;7:157-174.
Eibl MM. Immunol Allergy Clin North Am. 2008;28:737-764, viii.
Furusho K, et al. Lancet. 1983;2:1359.
Gallagher PE, Buckley RH. J Allergy Clin Immunol. 1982;69:120.
Guo Y, et al. Front Immunol. 2018;9:1299.
Imbach P, et al. Lancet. 1981;1:1228-31.
Kustiawan I. PLoS ONE. 2018;13: e0195729. https://doi.org/10.1371/journal.pone.0195729.
MRC Working Party on Hypogammaglobulinaemia. Hypogammaglobulinaemia in the United Kingdom. London: Her Majesty’s Stationery Office; 1971.